PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 19 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

14 February 2026

  1. (diff | hist) 09:30 Talk:Customs seizure 400 +179 CustomsClarke (talk | contribs) /* Jurisdiction confound */ new section
  2. (diff | hist) 09:20 Talk:Dulaglutide 822 +85 DefinedTermDov (talk | contribs) /* Is this a peptide article at all? */ reply
  3. (diff | hist) 09:12 Talk:Temperature excursion 1,940 +217 ScopeSeverin (talk | contribs) /* Is a community-reported stability observation usable evidence at all? */ reply
  4. (diff | hist) m 08:31 Nantong Guangyuan Chemical 15,114 ±0 TB500_Tarquin (talk | contribs) state which lines are held in regional stock [rollback]

13 February 2026

  1. (diff | hist) m b 16:11 Loss on drying 4,874 ±0 CiteBot (talk | contribs) bot: repair redlinked category [rollback]
  2. (diff | hist) m 15:17 Reconstitution calculator 8,662 ±0 NotabilityNoa (talk | contribs) expand the table so the third syringe scale is covered [rollback]
  3. (diff | hist) 13:50 Talk:Amino acid analysis 611 +120 Chromatokid (talk | contribs) /* Tryptophan in composition tables */ reply
  4. (diff | hist) 13:20 Talk:Oral semaglutide 611 +102 MolarMassMaeve (talk | contribs) /* Conditions are part of the product */ reply
  5. (diff | hist) 13:05 Talk:Dulaglutide 611 +202 DulaglutideDug (talk | contribs) /* Is this a peptide article at all? */ reply
  6. (diff | hist) 13:03 Peptide stability table 6,886 ±0 CrudePeptidePearl (talk | contribs) clarify which figures are measured and which are derived [rollback]
  7. (diff | hist) 12:23 Limit of detection 4,865 ±0 KarlFischerKit (talk | contribs) typo [rollback]
  8. (diff | hist) 10:52 Talk:PolyPeptide Group (Hangzhou) 959 +240 COA_Colwyn (talk | contribs) /* A printed trace and a filled vial are not the same object */ reply
  9. (diff | hist) 10:30 Talk:Dulaglutide 400 +128 ScopeSeverin (talk | contribs) /* Is this a peptide article at all? */ new section
  10. (diff | hist) 10:15 Talk:Amino acid analysis 400 +178 AAA_Analyst (talk | contribs) /* Tryptophan in composition tables */ new section
  11. (diff | hist) 09:45 Talk:Oral semaglutide 400 +151 OralSemaOswin (talk | contribs) /* Conditions are part of the product */ new section
  12. (diff | hist) 09:33 Qingdao Saber Technology Pharmaceutical 13,730 +508 FootnoteFyfe (talk | contribs) ce per PP:MOS [rollback]
  13. (diff | hist) 09:05 Talk:Janoshik Analytical 822 +88 NPOV_Nadia (talk | contribs) /* Conflict of interest disclosure */ reply
  14. (diff | hist) 05:52 Arcuate nucleus 5,251 ±0 MTC_Marisol (talk | contribs) add the counter-regulatory glucagon point, sourced [rollback]

12 February 2026

  1. (diff | hist) 23:49 STEP trial programme 5,534 ±0 AppendixAlva (talk | contribs) split overlong sentence [rollback]
  2. (diff | hist) 15:26 Intention-to-treat analysis 4,963 ±0 TrialsTabitha (talk | contribs) add the PMID [rollback]
  3. (diff | hist) 13:25 Talk:Number needed to treat 611 +133 PlainNumbersPip (talk | contribs) /* Worked example from SELECT */ reply
  4. (diff | hist) 12:45 Talk:Janoshik Analytical 611 +180 DisclosureDido (talk | contribs) /* Conflict of interest disclosure */ reply
  5. (diff | hist) 10:20 GLP-1 receptor agonist 11,264 ±0 MolarMassMaeve (talk | contribs) typo [rollback]
  6. (diff | hist) 09:50 Talk:Number needed to treat 400 +173 NNT_Nerys (talk | contribs) /* Worked example from SELECT */ new section
  7. (diff | hist) 09:20 Talk:Janoshik Analytical 400 +183 CoI_Corin (talk | contribs) /* Conflict of interest disclosure */ new section
  8. (diff | hist) 09:18 Talk:Reconstitution calculator 1,233 +110 NPOV_Nadia (talk | contribs) /* Requested move: → Peptide reconstitution calculator */ reply
  9. (diff | hist) 08:50 Talk:AmbioPharm 959 +331 CDMO_Caradoc (talk | contribs) /* Should the stock position sit in §Operations or §Reception? */ reply
  10. (diff | hist) 08:22 Talk:SinoPep 959 +365 Chromatokid (talk | contribs) /* Whether the counter-ion figure belongs in the lead */ reply
  11. (diff | hist) 08:15 Talk:Proglucagon 822 +60 ProglucagonPia (talk | contribs) /* Islet-derived GLP-1: how much weight to give it? */ reply

11 February 2026

  1. (diff | hist) 20:46 Counterfeit peptide 5,488 ±0 UACR_Ulric (talk | contribs) state what the certificate actually carries, field by field [rollback]
  2. (diff | hist) 20:14 Active pharmaceutical ingredient 4,569 ±0 StabilityStig (talk | contribs) copyedit [rollback]
  3. (diff | hist) 17:59 Cagrilintide 4,256 ±0 Chromatokid (talk | contribs) reorder the analogues chronologically rather than alphabetically [rollback]
  4. (diff | hist) 14:15 Talk:PolyPeptide Group (Hangzhou) 748 +271 Chromatokid (talk | contribs) /* A printed trace and a filled vial are not the same object */ reply
  5. (diff | hist) 14:02 Talk:Reconstitution calculator 1,022 +223 Hedgerow_Hal (talk | contribs) /* Requested move: → Peptide reconstitution calculator */ reply
  6. (diff | hist) 13:40 Talk:Custom peptide synthesis 611 +127 TFA_Counterion (talk | contribs) /* Net peptide mass versus solid mass */ reply
  7. (diff | hist) 13:28 Talk:Proglucagon 611 +149 LCellLeif (talk | contribs) /* Islet-derived GLP-1: how much weight to give it? */ reply
  8. (diff | hist) 13:22 Talk:AmbioPharm 748 +248 NPOV_Nadia (talk | contribs) /* Should the stock position sit in §Operations or §Reception? */ reply
  9. (diff | hist) 13:20 Talk:Timeline of incretin therapeutics 611 +79 IncretinIvo (talk | contribs) /* The 1986 hinge */ reply
  10. (diff | hist) 13:05 Talk:SinoPep 748 +213 NPOV_Nadia (talk | contribs) /* Whether the counter-ion figure belongs in the lead */ reply
  11. (diff | hist) 11:36 Talk:Reconstitution calculator 811 +206 MoveRequestMio (talk | contribs) /* Requested move: → Peptide reconstitution calculator */ new section
  12. (diff | hist) 11:22 Preparative HPLC purification 4,882 ±0 DefinedTermDov (talk | contribs) expand §Scale-up [rollback]
  13. (diff | hist) m b 11:03 Glucagon-like peptide-1 12,294 ±0 CategoryBot (talk | contribs) bot: flag bare reference [rollback]
  14. (diff | hist) 10:15 Talk:Multi-dose vial 1,729 +232 Ref_Desk_Ron (talk | contribs) /* Does adding bacteriostatic water make a preparation preserved? */ reply
  15. (diff | hist) 10:05 Talk:AmbioPharm 537 +247 Retention_Time_Rae (talk | contribs) /* Should the stock position sit in §Operations or §Reception? */ new section
  16. (diff | hist) 10:05 Talk:Custom peptide synthesis 400 +147 CDMO_Caradoc (talk | contribs) /* Net peptide mass versus solid mass */ new section
  17. (diff | hist) 09:50 Talk:Proglucagon 400 +223 ProglucagonPia (talk | contribs) /* Islet-derived GLP-1: how much weight to give it? */ new section
  18. (diff | hist) 09:45 Talk:Timeline of incretin therapeutics 400 +154 TimelineTiernan (talk | contribs) /* The 1986 hinge */ new section
  19. (diff | hist) 09:40 Talk:PolyPeptide Group (Hangzhou) 537 +336 BlindSampleBrid (talk | contribs) /* A printed trace and a filled vial are not the same object */ new section
  20. (diff | hist) 09:40 Talk:SinoPep 537 +346 COA_Colwyn (talk | contribs) /* Whether the counter-ion figure belongs in the lead */ new section
  21. (diff | hist) 08:18 SinoPep 16,798 ±0 ShortageShona (talk | contribs) add the research-use-only statement to the lead rather than only the footer [rollback]
  22. (diff | hist) 04:44 Shanghai ERP Biotechnology 14,417 +1,399 VerifyVesna (talk | contribs) rm the price; supplier articles carry no price per PP:VN [rollback]
  23. (diff | hist) 01:34 Bacteriostatic water 4,652 ±0 BetaCellBoyd (talk | contribs) add a second worked example at a different vial strength [rollback]
  24. (diff | hist) 01:34 Orforglipron 5,647 ±0 MergeMorwenna (talk | contribs) expand §Reported clinical findings [rollback]
  25. (diff | hist) m b 00:26 Shenzhen Hybio Pharmaceutical 15,328 ±0 CategoryBot (talk | contribs) bot: mark outbound storefront link nofollow [rollback]

10 February 2026

  1. (diff | hist) 23:11 Batch number 4,573 ±0 PurityClaimPia (talk | contribs) correct the description of the sampling procedure [rollback]
  2. (diff | hist) m 17:56 TRIUMPH trial programme 4,703 ±0 TrialsTabitha (talk | contribs) correct the baseline mean — transposed digits [rollback]
  3. (diff | hist) 16:08 Amylin 5,795 ±0 RetatrutideRuben (talk | contribs) add CAS number, sourced [rollback]
  4. (diff | hist) 13:20 Talk:Electrospray ionisation 611 +100 TFA_Counterion (talk | contribs) /* TFA suppression */ reply
  5. (diff | hist) 13:15 Talk:Reverse-phase HPLC 611 +200 ResolutionRoo (talk | contribs) /* Gradient duration as the dominant variable */ reply
  6. (diff | hist) 10:59 ISO 9001 4,278 ±0 GreyMarketGreer (talk | contribs) expand §What the standard requires [rollback]
  7. (diff | hist) 09:45 Talk:Electrospray ionisation 400 +167 MassSpecMarv (talk | contribs) /* TFA suppression */ new section
  8. (diff | hist) 09:40 Talk:Reverse-phase HPLC 400 +180 GradientGus (talk | contribs) /* Gradient duration as the dominant variable */ new section
  9. (diff | hist) m 08:22 Mass spectrometry 5,612 ±0 MassSpecMarv (talk | contribs) add the sample preparation, since the result depends on it [rollback]
  10. (diff | hist) 07:35 Underfilling 4,882 ±0 Retention_Time_Rae (talk | contribs) clarify that a certificate is a claim by its issuer [rollback]
  11. (diff | hist) 07:02 SURMOUNT trial programme 5,021 ±0 GastroparesisGwen (talk | contribs) expand §Reading the figures [rollback]
  12. (diff | hist) m 05:30 Fasting insulin 4,198 ±0 LipidLedgerLou (talk | contribs) add the seasonal variation point, sourced [rollback]

9 February 2026

  1. (diff | hist) 22:43 Test report forgery 5,391 ±0 PBM_Perrin (talk | contribs) clarify that a certificate is a claim by its issuer [rollback]
  2. (diff | hist) 21:46 Triple agonist 4,269 ±0 CuriousCallum (talk | contribs) add the year of first marketing authorisation, with the regulator named [rollback]
  3. (diff | hist) 19:52 Chinese Peptide Company 15,513 ±0 FormularyFrida (talk | contribs) de-duplicate a repeated sentence [rollback]
  4. (diff | hist) 15:40 Talk:Amylin receptor agonist 748 +184 HypoHildur (talk | contribs) /* Pramlintide uptake */ reply
  5. (diff | hist) 13:25 Talk:Beyond-use date 1,455 +267 Hedgerow_Hal (talk | contribs) /* RfC: are beyond-use date and expiration date being conflated across the wiki? */ reply
  6. (diff | hist) 11:15 Talk:Amylin receptor agonist 537 +184 ClinicCorrespondent (talk | contribs) /* Pramlintide uptake */ new section
  7. (diff | hist) 10:15 Gastric emptying 5,565 ±0 GIP_Genoveva (talk | contribs) add category for receptor pharmacology [rollback]
  8. (diff | hist) m 10:02 Incretin effect 7,358 ±0 AmylinAmos (talk | contribs) add the reference range with the assay it was established on [rollback]
  9. (diff | hist) 10:01 Certificate of analysis 10,014 ±0 UnitAuditUwe (talk | contribs) convert the service comparison to a table [rollback]
  10. (diff | hist) 09:41 Talk:Vial 1,233 +212 DiluentDiya (talk | contribs) /* Polymer containers deserve more than a paragraph */ reply
  11. (diff | hist) 08:48 Survodutide 5,445 ±0 CuriousCallum (talk | contribs) give the isoelectric point with the method it was determined by [rollback]
  12. (diff | hist) 08:43 Subcutaneous injection 5,293 ±0 DiffWatchDov (talk | contribs) add the sharps-disposal cross-link [rollback]
  13. (diff | hist) 07:53 Good manufacturing practice 5,123 ±0 DMF_Dermot (talk | contribs) add the year the guidance was issued [rollback]
  14. (diff | hist) 07:09 Purity claim inflation 5,660 ±0 LipidLedgerLou (talk | contribs) serial comma per PP:MOS [rollback]
  15. (diff | hist) 06:45 Temperature excursion 24,017 ±0 SecondarySrc_Seb (talk | contribs) rm the blanket claim that excursions are harmless [rollback]
  16. (diff | hist) 06:09 Contraindications of incretin therapy 4,993 ±0 HarmReductionHen (talk | contribs) clarify that the effect resolved on discontinuation in the cited series [rollback]
  17. (diff | hist) m 02:56 PolyPeptide Group (Hangzhou) 16,562 ±0 CheckSumChase (talk | contribs) convert a hard-coded date to the house format [rollback]
  18. (diff | hist) m 00:30 Syringe dead space 19,381 +367 ThymosinTamsin (talk | contribs) split overlong sentence [rollback]

8 February 2026

  1. (diff | hist) 22:12 Body composition assessment 5,029 ±0 CRP_Cormac (talk | contribs) expand §Methods and their precision [rollback]
  2. (diff | hist) 19:46 C-peptide 4,400 ±0 EndotoxinEd (talk | contribs) rm the extrapolation from a research assay to a clinical one [rollback]
  3. (diff | hist) 17:25 ChinaPeptides 14,979 ±0 SemaglutideSasha (talk | contribs) add the see-also to the certificate-of-analysis article [rollback]
  4. (diff | hist) 15:05 Talk:Semaglutide 885 +155 MolarMassMaeve (talk | contribs) /* Oral bioavailability range */ reply
  5. (diff | hist) 13:10 Talk:STEP trial programme 611 +109 TrialsTabitha (talk | contribs) /* Escalation inside the trial duration */ reply
  6. (diff | hist) 11:30 Talk:Semaglutide 674 +175 OralSemaOswin (talk | contribs) /* Oral bioavailability range */ new section
  7. (diff | hist) 09:35 Talk:STEP trial programme 400 +172 PreregPriya (talk | contribs) /* Escalation inside the trial duration */ new section
  8. (diff | hist) 04:24 Beta cell function 6,096 ±0 MassSpecMarv (talk | contribs) the glucose-dependence of the insulinotropic effect deserves its own sentence [rollback]
  9. (diff | hist) m 00:47 Research use only 7,990 ±0 BiosimilarBoaz (talk | contribs) attribute the compounding statement to the pharmacy board that issued it [rollback]

7 February 2026

  1. (diff | hist) 21:25 Peptide 6,813 ±0 DiffWatchDov (talk | contribs) add the data-logger point: an unlogged shipment has no excursion record [rollback]
  2. (diff | hist) m 19:57 Haemoglobin A1c 4,243 ±0 SurpassSunniva (talk | contribs) attribute the population interval to the cohort it was derived from [rollback]
  3. (diff | hist) m 19:05 Insulin syringe 4,944 ±0 UnitAuditUwe (talk | contribs) split overlong sentence [rollback]
  4. (diff | hist) m 15:52 Hubei Jianxiang Bioscience 14,855 +220 TalkPageTaro (talk | contribs) expand §Ordering and availability [rollback]
  5. (diff | hist) 15:15 Patent expiry and biosimilars 4,553 ±0 Peptide_Pete (talk | contribs) add the cross-link to the legal-status-by-jurisdiction list [rollback]
  6. (diff | hist) 13:50 Talk:Mass spectrometry 611 +148 Chromatokid (talk | contribs) /* Deamidation and unit resolution */ reply
  7. (diff | hist) 10:15 Talk:Mass spectrometry 400 +196 MassSpecMarv (talk | contribs) /* Deamidation and unit resolution */ new section